eFFECTOR Therapeutics, a biopharmaceutical company focused on pioneering the development of selective translation regulation inhibitors, went public via a SPAC merger with Locust Walk Acquisition, a blank-check company, in a $419m deal. The deal includes a $60m PIPE financing of common stock by Abingworth, SR One, The Column Group and US Venture Partners, Altitude Life Science Ventures, Sectoral Asset Management, Pfizer Ventures, Alexandria Venture Investments, BioMed Ventures and Osage University Partners. “With a strong pipeline with multiple near-term data readouts, we are excited to see eFFECTOR Therapeutics take this very important next step in its evolution. eFFECTOR’s expert team, along with the strategy to accelerate the development of innovative programs that are already progressing in the clinic, makes the Company well-positioned in its efforts to transform treatments for patients with cancer," Chris Ehrlich, LWAC CEO.